NCT00280397View on ClinicalTrials.gov

An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

September 30, 2008

Study Completion Date

November 30, 2008

Conditions
Cancer: Solid Tumors
Interventions
DRUG

E7080

E7080 is administered orally twice a day for 2 weeks to patients with solid tumors that are resistant to approved conventional therapies or for which no appropriate treatment is available.

Trial Locations (1)

104-0045

Tokyo

All Listed Sponsors
lead

Eisai Inc.

INDUSTRY

NCT00280397 - An Open Label Phase I Dose Escalation Study of E7080 Administered to Patients With Solid Tumors | Biotech Hunter | Biotech Hunter